Jun 2026 (Q2 FY26) — Aug 11, 2026
Harvard Bioscience Q2 FY26 — Double-Digit Revenue Growth and Raised Full-Year Outlook
Read the full callHarvard Bioscience (HBIO) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Harvard Bioscience earnings: last reported Tue, 11 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 22.7 | +11.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -4.3 | −0.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -2.9 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$8.09 0.00% · $0
Performance +113.5% 1Y
1Y: $3.79 on 17 Oct 2025 → $8.09. High $8.56 (6 Oct 2026), low $3.79 (17 Oct 2025).
- Previous close
- $8.09
- 52-week range
- $3.98 – $8.56
- One year
- +103.27%
Overview
- Symbol
- HBIO
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Harvard Bioscience earnings calls (HBIO)
Financials
What the filings say
Net profit, year on year: −28% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 22 | 25 | 22 | 20 | 21 | 24 | 21 | 23 |
| Operating profit | -2 | 0 | -50 | -1 | 0 | 2 | -1 | -1 |
| Operating margin | −8.5% | 0.0% | −228.1% | −4.0% | 1.0% | 7.2% | −5.7% | −4.3% |
| Other income | -3 | 1 | -1 | -1 | -1 | -5 | -2 | -2 |
| Profit before tax | -4 | 1 | -51 | -2 | -1 | -3 | -3 | -3 |
| Tax rate | −6.9% | 97.0% | 0.9% | −1.2% | −8.6% | 11.1% | −3.5% | −0.5% |
| Net profit | -5 | 0 | -50 | -2 | -1 | -3 | -3 | -3 |
| EPS ($ per share) | -0.11 | — | -11.42 | -0.52 | -0.03 | — | -0.77 | -0.64 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -120 | -125 | -132 | -133 | -142 | -146 | -158 | -215 |
| Total liabilities | 86 | 83 | 80 | 79 | 73 | 64 | 63 | 66 |
| Fixed assets | 6 | 5 | 4 | 3 | 3 | 4 | 5 | 5 |
| Total assets | 169 | 165 | 156 | 162 | 145 | 137 | 127 | 80 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 3 | 8 | 9 | 1 | 1 | 14 | 1 | 7 |
| Cash from investing | -54 | -0 | -1 | -1 | -2 | -2 | -1 | -2 |
| Cash from financing | 53 | -8 | -8 | -0 | -3 | -12 | -0 | -1 |
| Net cash flow | 2 | 0 | -0 | -0 | -3 | -0 | -0 | 5 |
| Capital expenditure | -1 | -1 | -1 | -1 | -2 | -2 | -3 | -1 |
| Free cash flow | 2 | 7 | 8 | 0 | -0 | 12 | -1 | 5 |
Insider filings
13 filings between Dec 17, 2025 and Jun 9, 2026.
Open market
decisions to buy or sellPurchases
$202.4K
5 purchases by 4 insiders
Sales
None
No insider sold shares.
Compensation
not trading decisions- 8
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Snider William | $103.6K | — | Mar 17, 2026 |
| DENELSKY STEPHEN J | $48.7K | — | Mar 17, 2026 |
| Duke John D | $25.1K | — | Mar 16, 2026 |
| Frost Mark T | $25.0K | — | Mar 16, 2026 |
Latest filings (33)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jun 9, 2026 | Eade Katherine A. Director | Award | 16,556 | $0 |
| Jun 9, 2026 | Gagnon Robert E. Director | Award | 16,556 | $0 |
| Jun 9, 2026 | DENELSKY STEPHEN J Director | Award | 16,556 | $0 |
| Jun 9, 2026 | Snider William Director | Award | 16,556 | $0 |
| Jun 9, 2026 | Benson Seth Benjamin Director | Award | 16,556 | $0 |
| Mar 20, 2026 | Frost Mark T Chief Financial Officer | Award | 30,000 | $0 |
| Mar 20, 2026 | Duke John D Chief Executive Officer | Award | 75,000 | $0 |
| Mar 17, 2026 | DENELSKY STEPHEN J Director | Purchase | 10,000 | $48.7K |
| Mar 17, 2026 | Snider William Director | Purchase | 8,475 | $41.1K |
| Mar 16, 2026 | Frost Mark T Chief Financial Officer | Purchase | 5,000 | $25.0K |
| Mar 16, 2026 | Snider William Director | Purchase | 12,525 | $62.5K |
| Mar 16, 2026 | Duke John D Chief Executive Officer | Purchase | 5,000 | $25.1K |
| Dec 17, 2025 | Snider William Director | Award | 110,000 | $0 |
| Sep 5, 2025 | DENELSKY STEPHEN J Director | Award | 110,000 | $0 |
| Aug 15, 2025 | Green James W Director | Disposition to issuer | 119,332 | $0 |
| Aug 15, 2025 | Green James W Director | Disposition to issuer | 49,048 | $0 |
| Aug 15, 2025 | Green James W Director | Tax withheld | 33,200 | $17.6K |
| Aug 15, 2025 | Green James W Director | Tax withheld | 11,540 | $6.1K |
| Aug 15, 2025 | Green James W Director | Disposition to issuer | 66,036 | $0 |
| Aug 15, 2025 | Green James W Director | Disposition to issuer | 113,366 | $0 |
| Aug 8, 2025 | Duke John D Chief Executive Officer | Award | 500,000 | $0 |
| Aug 8, 2025 | Duke John D Chief Executive Officer | Award | 500,000 | $0 |
| Jul 16, 2025 | Benson Seth Benjamin Director | Award | 110,000 | $0 |
| Jul 16, 2025 | Gagnon Robert E. Director | Award | 110,000 | $0 |
| Jul 16, 2025 | Eade Katherine A. Director | Award | 110,000 | $0 |
| May 12, 2025 | Frost Mark T Interim CFO | Award | 100,000 | $0 |
| Mar 19, 2025 | Green James W Chief Executive Officer | Tax withheld | 38,413 | $26.5K |
| Mar 19, 2025 | Cote Jennifer Chief Financial Officer | Tax withheld | 5,687 | $3.9K |
| Dec 31, 2024 | Green James W Chief Executive Officer | Disposition to issuer | 145,365 | $0 |
| Dec 29, 2024 | Cote Jennifer Chief Financial Officer | Tax withheld | 4,731 | $9.4K |
| Dec 29, 2024 | Cote Jennifer Chief Financial Officer | Tax withheld | 3,797 | $7.5K |
| Dec 29, 2024 | Green James W Chief Executive Officer | Tax withheld | 56,915 | $112.7K |
| Dec 29, 2024 | Green James W Chief Executive Officer | Tax withheld | 25,310 | $50.1K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for HARVARD BIOSCIENCE INC
Free account. Everything above stays public.
Write why you follow HARVARD BIOSCIENCE INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading